## Matthew W Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/989629/publications.pdf

Version: 2024-02-01

117 papers 12,530 citations

41344 49 h-index 29157 104 g-index

127 all docs

127 docs citations

times ranked

127

5251 citing authors

#	Article	IF	CITATIONS
1	Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 2016, 30, 1181-1197.	4.0	1,221
2	WITHIN-SUBJECT COMPARISON OF REAL AND HYPOTHETICAL MONEY REWARDS IN DELAY DISCOUNTING. Journal of the Experimental Analysis of Behavior, 2002, 77, 129-146.	1.1	771
3	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 481.	11.0	648
4	Pilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 2014, 28, 983-992.	4.0	613
5	Delay discounting in current and never-before cigarette smokers: Similarities and differences across commodity, sign, and magnitude Journal of Abnormal Psychology, 2003, 112, 382-392.	1.9	519
6	The Behavioral Economics of Substance Use Disorders: Reinforcement Pathologies and Their Repair. Annual Review of Clinical Psychology, 2014, 10, 641-677.	12.3	501
7	Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 2017, 43, 55-60.	2.1	430
8	An algorithm for identifying nonsystematic delay-discounting data Experimental and Clinical Psychopharmacology, 2008, 16, 264-274.	1.8	423
9	Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 2015, 29, 1182-1190.	4.0	318
10	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews, 2015, 7, 157-164.	3.4	306
11	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 2016, 30, 1268-1278.	4.0	303
12	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function., 2019, 197, 83-102.		296
13	Delay discounting in currently using and currently abstinent cocaine-dependent outpatients and non-drug-using matched controls. Addictive Behaviors, 2006, 31, 1290-1294.	3.0	290
14	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 2018, 32, 49-69.	4.0	285
15	Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 2015, 29, 280-288.	4.0	278
16	Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the Scientific Study of Religion, 2012, 51, 721-737.	1.5	243
17	Moderate drug use and delay discounting: A comparison of heavy, light, and never smokers Experimental and Clinical Psychopharmacology, 2007, 15, 187-194.	1.8	201
18	Delay discounting in current and former marijuana-dependent individuals Experimental and Clinical Psychopharmacology, 2010, 18, 99-107.	1.8	184

#	Article	IF	Citations
19	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018, 142, 143-166.	4.1	184
20	The Sexual Discounting Task: HIV risk behavior and the discounting of delayed sexual rewards in cocaine dependence. Drug and Alcohol Dependence, 2012, 123, 15-21.	3.2	180
21	Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 2017, 14, 734-740.	4.4	180
22	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 2016, 30, 1279-1295.	4.0	175
23	Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 250-258.	4.8	172
24	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 2022, 36, 151-158.	4.0	162
25	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 2018, 32, 756-769.	4.0	152
26	Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 2019, 33, 1088-1101.	4.0	145
27	Ramelteon. Archives of General Psychiatry, 2006, 63, 1149.	12.3	134
28	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 2019, 14, e0214377.	2.5	132
29	Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 2011, 115, 150-155.	3.2	120
30	Demand curves for hypothetical cocaine in cocaine-dependent individuals. Psychopharmacology, 2014, 231, 889-897.	3.1	118
31	Psychedelic medicine: a re-emerging therapeutic paradigm. Cmaj, 2015, 187, 1054-1059.	2.0	108
32	Rejecting impulsivity as a psychological construct: A theoretical, empirical, and sociocultural argument Psychological Review, 2021, 128, 336-361.	3.8	105
33	Cocaine administration dose-dependently increases sexual desire and decreases condom use likelihood: The role of delay and probability discounting in connecting cocaine with HIV. Psychopharmacology, 2017, 234, 599-612.	3.1	96
34	Sexual discounting among high-risk youth ages 18–24: Implications for sexual and substance use risk behaviors Experimental and Clinical Psychopharmacology, 2015, 23, 49-58.	1.8	95
35	Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. Journal of the Experimental Analysis of Behavior, 2015, 103, 87-107.	1.1	93
36	Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and Alcohol Dependence, 2012, 123, 132-140.	3.2	92

#	Article	IF	CITATIONS
37	Examining delay discounting of condom-protected sex among opioid-dependent women and non-drug-using control women. Drug and Alcohol Dependence, 2014, 144, 53-60.	3.2	90
38	Characterizing use patterns and perceptions of relative harm in dual users of electronic and tobacco cigarettes Experimental and Clinical Psychopharmacology, 2015, 23, 494-503.	1.8	87
39	A randomized controlled trial of the effects of working memory training in methadone maintenance patients. Drug and Alcohol Dependence, 2015, 156, 38-46.	3.2	79
40	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry, 2019, 10, 955.	2.6	75
41	Delay and Probability Discounting of Sexual and Monetary Outcomes in Individuals with Cocaine Use Disorders and Matched Controls. PLoS ONE, 2015, 10, e0128641.	2.5	75
42	High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, 2012, 223, 1-15.	3.1	73
43	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology, 2018, 235, 521-534.	3.1	73
44	An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 2017, 31, 841-850.	4.0	72
45	Does being drunk or high cause HIV sexual risk behavior? A systematic review of drug administration studies. Pharmacology Biochemistry and Behavior, 2018, 164, 125-138.	2.9	66
46	Survey of entity encounter experiences occasioned by inhaled <i>N,N</i> -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 2020, 34, 1008-1020.	4.0	64
47	Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 2015, 29, 1041-1043.	4.0	62
48	Test–retest reliability and gender differences in the sexual discounting task among cocaine-dependent individuals Experimental and Clinical Psychopharmacology, 2013, 21, 277-286.	1.8	59
49	Who is â€~Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology, 2017, 31, 1056-1060.	4.0	59
50	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology, 2018, 235, 2915-2927.	3.1	58
51	Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. ACS Pharmacology and Translational Science, 2021, 4, 578-581.	4.9	55
52	Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 2017, 117, 155-160.	2.9	54
53	An efficient operant choice procedure for assessing delay discounting in humans: Initial validation in cocaine-dependent and control individuals Experimental and Clinical Psychopharmacology, 2012, 20, 191-204.	1.8	52
54	Behavioral economic substitutability of e-cigarettes, tobacco cigarettes, and nicotine gum. Journal of Psychopharmacology, 2017, 31, 851-860.	4.0	52

#	Article	IF	CITATIONS
55	Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. ACS Pharmacology and Translational Science, 2021, 4, 472-478.	4.9	51
56	Can psychedelic compounds play a part in drug dependence therapy?. British Journal of Psychiatry, 2015, 206, 1-3.	2.8	50
57	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 2021, 35, 353-361.	4.0	49
58	Alcohol Increases Delay and Probability Discounting of Condomâ€Protected Sex: A Novel Vector for Alcoholâ€Related HIV Transmission. Alcoholism: Clinical and Experimental Research, 2016, 40, 1339-1350.	2.4	48
59	Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. Frontiers in Psychology, 2022, 13, .	2.1	41
60	Psychedelics and health behaviour change. Journal of Psychopharmacology, 2022, 36, 12-19.	4.0	40
61	Examining Delay Discounting of Condom-Protected Sex Among Men Who Have Sex with Men Using Crowdsourcing Technology. AIDS and Behavior, 2015, 19, 1655-1665.	2.7	37
62	Psychedelics and Psychotherapy. Pharmacopsychiatry, 2021, 54, 167-175.	3.3	35
63	Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology, 2020, 237, 2293-2304.	3.1	32
64	The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. Scientific Reports, 2020, 10, 16392.	3.3	28
65	A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology, 2022, 36, 273-294.	4.0	28
66	Discounting of Condom-Protected Sex as a Measure of High Risk for Sexually Transmitted Infection Among College Students. Archives of Sexual Behavior, 2017, 46, 2187-2195.	1.9	27
67	Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1309-1314.	1.2	24
68	Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. Pain, 2016, 157, 1724-1732.	4.2	23
69	Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. Addictive Behaviors, 2017, 65, 81-86.	3.0	23
70	Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults. Journal of Caffeine Research, 2016, 6, 10-19.	0.9	22
71	Cocaine-dependent adults and recreational cocaine users are more likely than controls to choose immediate unsafe sex over delayed safer sex Experimental and Clinical Psychopharmacology, 2016, 24, 297-304.	1.8	22
72	Behavioral economic methods to inform infectious disease response: Prevention, testing, and vaccination in the COVID-19 pandemic. PLoS ONE, 2022, 17, e0258828.	2.5	22

#	Article	IF	Citations
73	Nicotine reinforcement in never-smokers. Psychopharmacology, 2015, 232, 4243-4252.	3.1	21
74	Sexual Probability Discounting: A Mechanism for Sexually Transmitted Infection Among Undergraduate Students. Archives of Sexual Behavior, 2019, 48, 495-505.	1.9	21
75	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy, 2021, 98, 103380.	3.3	21
76	Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. Adolescent Psychiatry (Hilversum,) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50 21
77	Cocaine dependent individuals discount future rewards more than future losses for both cocaine and monetary outcomes. Addictive Behaviors, 2015, 40, 132-136.	3.0	20
78	Morning administration of oral methamphetamine dose-dependently disrupts nighttime sleep in recreational stimulant users. Drug and Alcohol Dependence, 2017, 178, 291-295.	3.2	20
79	Working Memory Training for Adolescents With Cannabis Use Disorders: A Randomized Controlled Trial. Journal of Child and Adolescent Substance Abuse, 2018, 27, 211-226.	0.5	20
80	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. International Journal of Neuropsychopharmacology, 2021, 24, 615-623.	2.1	20
81	Sexual discounting: A systematic review of discounting processes and sexual behavior Experimental and Clinical Psychopharmacology, 2021, 29, 711-738.	1.8	20
82	Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. American Journal of Drug and Alcohol Abuse, 2021, 47, 444-454.	2.1	18
83	Initial examination of priming tasks to decrease delay discounting. Behavioural Processes, 2016, 128, 144-152.	1.1	15
84	Altered experiential, but not hypothetical, delay discounting in schizophrenia Journal of Abnormal Psychology, 2017, 126, 301-311.	1.9	15
85	Delay and probability discounting in cocaine use disorder: Comprehensive examination of money, cocaine, and health outcomes using gains and losses at multiple magnitudes Experimental and Clinical Psychopharmacology, 2020, 28, 724-738.	1.8	14
86	Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 2016, 30, 323-329.	4.0	12
87	Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. Journal of Psychopharmacology, 2020, 34, 654-662.	4.0	12
88	To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in selfâ€identified chronic pain patients. Addiction, 2018, 113, 67-79.	3.3	11
89	Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices in economically-vulnerable African-American young adults (EMERGE): protocol for a feasibility randomized clinical trial. Trials, 2019, 20, 439.	1.6	11
90	Demographic and sexual risk predictors of delay discounting of condom-protected sex. Psychology and Health, 2020, 35, 366-386.	2.2	11

#	Article	IF	Citations
91	Behavioral economics and safe sex: Examining condom use decisions from a reinforcer pathology framework. Journal of the Experimental Analysis of Behavior, 2021, 116, 149-165.	1.1	10
92	Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Current Topics in Behavioral Neurosciences, 2022, , 213-227.	1.7	10
93	Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting Experimental and Clinical Psychopharmacology, 2020, 28, 157-168.	1.8	9
94	Psychiatry might need some psychedelic therapy. International Review of Psychiatry, 2018, 30, 285-290.	2.8	8
95	Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting Experimental and Clinical Psychopharmacology, 2022, 30, 180-193.	1.8	8
96	Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine Experimental and Clinical Psychopharmacology, 2010, 18, 305-315.	1.8	7
97	Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence Psychology of Addictive Behaviors, 2015, 29, 237-246.	2.1	7
98	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports, 2022, 9, 48-58.	3.4	7
99	Graphic Warning Labels Affect Hypothetical Cigarette Purchasing Behavior among Smokers Living with HIV. International Journal of Environmental Research and Public Health, 2019, 16, 3380.	2.6	6
100	The Hotel Room Purchase Task: Effects of Gender and Partner Desirability on Demand for Hypothetical Sex in Individuals with Disordered Cocaine Use and Controls. Archives of Sexual Behavior, 2020, 49, 1251-1262.	1.9	6
101	Human behavioral pharmacology of psychedelics. Advances in Pharmacology, 2022, 93, 105-132.	2.0	6
102	LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods, 2013, 5, 7042.	2.7	5
103	Initial feasibility and validity of a prospective memory training program in a substance use treatment population Experimental and Clinical Psychopharmacology, 2016, 24, 390-399.	1.8	5
104	Microenterprise Intervention to Reduce Sexual Risk Behaviors and Increase Employment and HIV Preventive Practices Among Economically-Vulnerable African-American Young Adults (EMERGE): A Feasibility Randomized Clinical Trial. AIDS and Behavior, 2020, 24, 3545-3561.	2.7	5
105	The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity Experimental and Clinical Psychopharmacology, 2021, 29, 219-228.	1.8	5
106	Perceived risk of developing smoking-related disease among persons living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1329-1334.	1.2	4
107	Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Journal of Psychopharmacology, 2020, 34, 336-347.	4.0	4
108	Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?. Frontiers in Psychiatry, 2020, $11$ , 497.	2.6	4

#	Article	IF	CITATIONS
109	The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. Drug and Alcohol Dependence, 2020, 208, 107772.	3.2	4
110	Attention-Deficit/Hyperactivity Disorder Symptoms Are Associated with Greater Delay Discounting of Condom-Protected Sex and Money. Archives of Sexual Behavior, 2021, 50, 191-204.	1.9	4
111	Single- and cross-commodity discounting among adults who use alcohol and cannabis: Associations with tobacco use and clinical indicators. Drug and Alcohol Dependence, 2021, 229, 109082.	3.2	2
112	Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Message Surveys in African-American Young Adults Experiencing Homelessness and Unemployment: Single-Group Study. JMIR Formative Research, 2020, 4, e14833.	1.4	2
113	The Influence of Episodic Future Thinking and Graphic Warning Labels on Delay Discounting and Cigarette Demand. International Journal of Environmental Research and Public Health, 2021, 18, 12637.	2.6	2
114	At-risk drinking, operant demand, and cross-commodity discounting as predictors of drunk driving in underage college women. Behavioural Processes, 2022, 195, 104548.	1.1	2
115	Beyond Systematic and Unsystematic Responding: Latent Class Mixture Models to Characterize Response Patterns in Discounting Research. Frontiers in Behavioral Neuroscience, 2022, 16, 806944.	2.0	2
116	Ramelteon. CNS Drugs, 2005, 19, 1066-1067.	5.9	1
117	Pharmacological assistance for psychotherapy. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100017.	1.1	O